[1] Landis S.Murray T, Bolden S, et al.1998 cancer statistics[J].Cancer, 1998, 48:1-31.
[2] Lind P, Gallowitsch HJ, Mikosch, et al.Comparison of different tracers in the follow up of differentiated thyroid carcinoma[J].Acta Med Austriaca, 1999, 26 (4):115-117.
[3] Wang W, Macapinlac H, Larson SM, et al.18F-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)Ⅰ whole body scan and elevated serum thyoglobulin levels[J].J Clin Endocrinol Metab, 1999, 84(7):2291-2302.
[4] Stokkel MP, Klerk JH, Zeliseen PM, et al.The detection of recurrent differentiated thyroid cancer[J].Eur J Nucl Med, 1999, 26(12):1606-1609.
[5] Mauro F, Alberto S, Guido V, et al.Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases[J].J Nucl Med, 1998, 39(9):1542-1545.
[6] Alnafisi NS, Driedger AA, Coates G, et al.FDG PET in papillary thyroid carcinoma[J].J Nucl Med, 2000, 41 (6):1010-1015.
[7] Chung JK, So Y, Lee JS, et al.Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan[J].J Nucl Med, 1999, 40(6):986-992.
[8] Altenvoerde G, Lerch H, Kuwert T, et al.Positron emission tomography with differentiated thyroid carcicinoma, elevated thyroglobin levels, and negative iodine scans[J].Langenbecks Arch Chir, 1998, 383:160-163.
[9] Dietlein M, Scheidhauer K, Voth F, et al.Follow-up of differentiated thyroid cancer:what is the value of FDG and sestamibi in the diagnostic algorithm?[J].Nuklearmedizin, 1998, 37(1):12-17.
[10] Huang TS, Chieng PU, Chang CC, et al.Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma[J].J Endocrinol Inv, 1998, 21(6):392-398.
[11] Filesi M, Signore A, Ventroni G, et al.Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases[J].J Nucl Med, 1998, 39(9):1542-1546.
[12] Grunwald F, Kalicke T, Feine U, et al.Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer[J].Eur J Nucl Med, 1999, 26(12):1547-1552.
[13] Schlumberger M, Baudin E.Papillary and follicular thyroid carcinoma[J].N Engl JM ed, 338:297-306.
[14] Lind P, Kumning G, Matschning S, et al.The role of F-18 FDG PET in thyroid cancer[J].Acta Med Austriaca, 2000, 27(2):38-41.
[15] Wang W, Larson SM, Fazzari M, et al.Prognostic value of [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomographic scanning in patients with thyroid cancer[J].J Clin Endocrinol Metab, 2000, 85(3):1107-1113.
[16] Wang W, Larson SM, Fazzari M, et al.Resistance of FDG-PET positive metastatiic thyroid carcinoma leisions to treatment with radioactive iodine[J].Thyroid, 1999, 9(Suppl 1):32.
[17] Feine U, Lietzenmayer R, Hanke JP, et al.Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer[J].J Nucl Med, 1996, 37:1468-1472.